Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/216344
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

The peptidoglycan and biofilm matrix of Staphylococcus epidermidis undergo structural changes when exposed to human platelets

AutorLoza-Correa, María; Ayala, Juan A.; Perelman, Iris; Hubbard, Keith; Yi, Qi-Long; Taha, Mariam; Pedro, Miguel Ángel de CSIC; Ramirez-Arcos, Sandra
Fecha de publicación25-jun-2019
EditorPublic Library of Science
CitaciónPLoS ONE 14 (2019)
ResumenStaphylococcus epidermidis is a bacterium frequently isolated from contaminated platelet concentrates (PCs), a blood product used to treat bleeding disorders in transfusion patients. PCs offer an accidental niche for colonization of S. epidermidis by forming biofilms and thus avoiding clearance by immune factors present in this milieu. Using biochemical and microscopy techniques, we investigated the structural changes of the peptidoglycan (PG) and the biofilm matrix of S. epidermidis biofilms formed in whole-blood derived PCs compared to biofilms grown in glucose-supplemented trypticase soy broth (TSBg). Both, the PG and the biofilm matrix are primary mechanisms of defense against environmental stress. Here we show that in PCs, the S. epidermidis biofilm matrix is mainly of a proteinaceous nature with extracellular DNA, in contrast to the predominant polysaccharide nature of the biofilm matrix formed in TSBg cultures. PG profile studies demonstrated that the PG of biofilm cells remodels during PC storage displaying fewer muropeptides variants than those observed in TSBg. The PG muropeptides contain two chemical modifications (amidation and O-acetylation) previously associated with resistance to antimicrobial agents by other staphylococci. Our study highlights two key structural features of S. epidermidis that are remodeled when exposed to human platelets and could be used as targets to reduce septic transfusions events.
Versión del editorhttp://dx.doi.org/10.1371/journal.pone.0211132
URIhttp://hdl.handle.net/10261/216344
DOI10.1371/journal.pone.0211132
Identificadoresdoi: 10.1371/journal.pone.0211132
issn: 1932-6203
Aparece en las colecciones: (CBM) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
AyalaJA_Thepeptidoglycan.pdf2,23 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

9
checked on 28-abr-2024

SCOPUSTM   
Citations

13
checked on 24-abr-2024

WEB OF SCIENCETM
Citations

10
checked on 29-feb-2024

Page view(s)

103
checked on 28-abr-2024

Download(s)

63
checked on 28-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons